SUMMARY A randomized, double-blind, clinical 
INTRODUCTION
The biomechanics theory points to the existence of a mechanical balance in the normal spine such as intervertebral joints and disks, ligaments and cervical muscles, where the function is to maintain a balance between the internal and external forces in the cervical region. Cervical Spondylosis is the most common cause of neck pain. The normal structure of the cervical spine is depicted in Figure 1 .
Cervical Spondylosis is a generalized process encompassing a sequence of degenerative changes in the cervical intervertebral discs, including varying degrees of disc degeneration and dehydration, loss of disc height and normal lordosis, osteophyte formation, hypertrophied facet joint, spinal stenosis, and hypertrophy of the ligamentum flavum. Cervical spondylosis is the most common disorder of the cervical spine after 45 years of age. However, as there are age-related degenerative changes affecting the cervical spine that are equally present in symptomatic and asymptomatic subjects, clinically evident pathological changes occurring in the cervical spine are superimposed upon and may be difficult to differentiate from the normal aging process (1, 2) .
Cervical spondylosis can be classified according to the main site of the disorder (nerve roots, vertebral artery, spinal cord and sympathetic nerves). The main symptom of cervical spondylosis is intermittent neck and/or referred pain (referred pain may be experienced in the shoulder, arm, scalp or chest) in middle-aged and elderly patients in the absence of neurological signs.
Pain associated with cervical spondylosis usually responds to activity modification, neck immobilization and isometric exercises, but in some instances some form of therapy should be applied. In addition to surgical procedures, cervical spondylosis may be relieved with rest, cervical orthosis or cervical traction, but in most cases pharmacological treatment is required. For milder symptoms, a nonsteroidal antiinflammatory drug can be used, but refractory cases may require a short course of oral steroids.
Other symptoms of cervical spondylosis include loss of sensation or abnormal sensations in the shoulder, arms or, rarely, legs, weakness of the arms or, rarely, legs, difficulty moving the head, neck stiffness that progressively worsens, headaches (particularly in the back of the head), loss of control of the bladder or bowels (if spinal cord is compressed), loss of balance, tinnitus and muscle weakness in the shoulders, arms or hands. Left to its natural course, the disease can progress to chronic neck pain, progressive loss of muscle function or feeling, permanent disability, fecal or urinary incontinence.
Eperisone hydrochloride (Myonal) (3-5) is commonly used as a muscle relaxant. It has been satisfactorily used in patients with spastic paralysis (6), lower back pain (7) (8) (9) (10) (11) , stiff shoulder or other shoulder armropathies (11) (12) (13) , other brachialgias or ischialgias (14) , as well as in orthopedic surgery (15) . Eperisone is claimed to relax both skeletal muscle and vascular smooth muscle, and it has a variety of other pharmacological effects such as improvement of circulation, suppression of pain reflex and reduction of muscular hypertonic symptoms. The objective of this trial was to determine the efficacy and safety of eperisone at a dose of 50 mg t.i.d. in patients with cervical spondylosis.
MATERIALS AND METHODS

Subjects
The recruitment of patients started in October 1994 and was completed in January 1997. A total of 215 patients aged 19-79 years were included in the trial. The subjects were selected in accordance with the inclusion/exclusion criteria set out in the protocol. Cervical spondylosis was confirmed in all patients through X-ray examination and blood investigation. Patients with mental disorders or clouding of consciousness were excluded. Patients suffering from ataxia, dementia, epilepsy, severe muscle contractures or serious diseases (spinal tumors, infections and fractures) as well as pregnant women or women suspected to be pregnant were also excluded. The protocol allowed the investigators to also exclude any patient deemed unfit for the trial due to any other diseases.
Before starting the screening for the trial, the nature and purpose of the study was explained to all the patients and written informed consent was obtained from all of them.
Study design
The trial was conducted in two centers, the Alexandra Hospital and the National University Hospital of Singapore. The protocoJ followed a randomized, doubleblind, placebo-controlled, parallel-group design. The total duration of the trial was 6 weeks. The subjects were randomized into two intervention groups. One group received 50 mg eperisone three times daily while the other received a matching placebo.
The assessments were carried out at baseline (pretreatment), and at 1, 3 and 6 weeks post-treatment using both subjective and objective methods. All data was collected and recorded in the standardized case report forms (CRFs) to be statistically analyzed by an independent organization.
Efficacy parameters
Subjective parameters such as pain, headache, kinesalgia, stiffness, numbness, tenderness and sensory disorders were measured with a pain scale. Objective parameters (range of motion of neck and shoulders) were measured using a goniometer.
Safety
Adverse events were monitored through scheduled questioning. All the events reported by patients noted by attending personnel were recorded with date of onset, duration, intensity and physician's opinion of causality and outcome in the case report form. Laboratory parameters assessed included erythrocyte and leukocyte counts, hemoglobin, hematocrit, erythrocyte sedimentation rate, alkaline phosphatase, alanine transferase, creatinine and rheumatoid factor.
Statistical analysis
The planned population of 100 patients in each group was based on the review of previous clinical trials of eperisone on cervical spondylosis, taking into account a potential withdrawal rate of 20%. Statistical analyses were performed only on the completed cases (per protocol analysis) with a drop-out rate of 26.9%. The results were not expected to be significantly different from those of the intent-to-treat population. Two-sided Fisher's exact test was used, and a p value of ≤ 0.05 was taken as statistically significant.
RESULTS
From the 215 subjects initially included in the trial, 58 (26.9%) were withdrawn due to poor compliance, lack of efficacy, adverse reactions or death. The remaining 157 subjects successfully completing the trial received eperisone (75 patients) or placebo (82 patients) according to the protocol, with no differences in demographical parameters among the two groups (Table 1) . At baseline, 17 and 18 patients in the eperisone and placebo groups, respectively, had little or no pain. Statistical analyses were performed for subjects with mild to severe and moderate to severe neck pain at baseline using two-sided Fisher's exact test.
The overall impression of the results showed a trend toward improvement in both groups. A definite trend of improvement for pain in the nuchal region was apparent, placebo (Fig. 3) . Range of motion scores, including lateral flexion, flexion/extension and axial lateral extension, also improved with eperisone compared to placebo, especially at the end of the third week of treatment (Fig.  4) . However, no significant changes were observed in both groups with regards to numbness, which at baseline showed low symptom scores.
The incidence of adverse effects in patients treated with eperisone was 4.2%.
DISCUSSION
Eperisone has been tested as a muscle relaxant in a number of clinical trials in patients with different conditions, ranging from low back pain to cervical syndromes. In these trials, eperisone was well-tolerated and effective in improving signs and symptoms, especially pain and mobility, which are the most limiting for the patients. In this clinical trial we assayed the effect of eperisone in patients with cervical spondylosis, a very limiting syndrome as it affects the balance between intervertebral joints and disks, ligaments and cervical muscles that function to stabilize the cervical structures. The three-year (October 1994-January 1997), doubleblind clinical trial of eperisone in the treatment of cervical spondylosis was successfully completed. The statistical analysis of the data showed a definite improvement trend in the eperisone group, particularly as regards pain in the nuchal region. Subjects with mild nuchal pain at baseline were noted to significantly improve by the sixth treatment week (final assessment) when compared to the placebo group. The overall incidence of adverse reactions after eperisone treatment was 4.2%, which is comparable to that observed in the post-marketing surveillance study of eperisone in Japan carried out between 1982 and 1988 (a 3.4% incidence of adverse events was observed).
Tsuyama et al. (11) conducted a study on 613 patients with cervical syndrome, periarthritis of the shoulder or lumbago using eperisone at doses similar to those of this trial. The results showed that for cervical syndrome, 50.5% of the patients exhibited moderate to marked improvement, while 87.1% exhibited at least a slight to marked improvement. Improvement rate of pain in the nuchal region was 70.5%, with 20.7% of the patients experiencing disappearance of the symptom. These data agree in with the results of the present trial, in which, in spite of an insufficient population to show any statistically significant difference between the eperisone and placebo groups, the trends toward a clinical benefit are obvious, as can be seen in Figures 2 and 3 .
Shima et al. (9) also evaluated the efficacy of eperisone in tenderness associated with lumbago and cervical syndrome using a pressure threshold meter in 29 cases. They found a significant (p < 0.001) improvement in the severity of neck and shoulder tenderness after treatment with eperisone. These results, again, agree well with the symptomatological benefit of eperisone noted in our trial, in which pain was the symptom most responsive to treatment. It is important to note, however, that kinesalgia and range of motion, which globally constitute the three most clinically invalidating symptoms of cervical spondylosis, also responded to treatment with eperisone as compared to placebo.
Globally, therefore, the three reported trials of eperisone in patients with cervical syndrome, with an overall population of almost 1000 subjects, demonstrate the benefit of the drug in terms of pain, kinesalgia and range of motion.
The overall incidence of adverse reactions in our study (4.2%) was in accordance with the incidence found in extensive studies in Japan (287 patients with adverse reactions out of 11,296 patients included in clinical trials, which means an estimated incidence of 2.5%) (Eisai Co., Ltd., data on file). The main adverse reactions in this survey were weakness, abdominal pain, nausea, dizziness, anorexia, malaise, rash, somnolence, diarrhea, dyspepsia and vomiting, all of them of a mild to moderate intensity and with an incidence lower than 1%.
In conclusion, as reported in other studies on the safety and efficacy of eperisone in patients with cervical spondylosis or other types of osteoarticular pain (mainly due to osteoarthritis), this clinical trial in patients with cervical spondylosis confirms the usefulness of eperisone by primarily reducing pain and improving the range of motion of the neck. as seen in Figure 2 , with eperisone giving better results than placebo. Similar trends were observed for back pain and pain in arms and shoulders. Improvement of pain in the nuchal region was statistically significantly superior with eperisone treatment at week 6 ( Table 2) . Stiffness had a low score at baseline, indicating that this was not a major concern for the patients. Headache improved in both groups, with no significant differences among them. With regard to kinesalgia, the eperisone group showed a greater benefit as compared with 
